Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet

Core Viewpoint - Mineralys Therapeutics, Inc. (MLYS) has seen a 5.1% increase in share price over the past four weeks, closing at $38.91, with a potential upside of 27.6% based on Wall Street analysts' mean price target of $49.63 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $42.00 to a high of $56.00, with a standard deviation of $5.78, indicating variability among analysts [2] - The lowest estimate suggests a 7.9% increase from the current price, while the highest estimate indicates a 43.9% upside [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about MLYS's earnings prospects, as evidenced by a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, three earnings estimates have been revised upward, leading to a 6.7% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank - MLYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of MLYS's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]